William WellsChairman of the Board

Mr. Wells has served as Chairman since December 2014 and has been a member of our board of directors since inception. Since 2000, Mr. Wells has served as President of Pope Asset Management, LLC, a registered investment advisor offering financial asset management services to high net worth investors. Mr. Wells is the founder and primary portfolio manager for Pope Asset Management, LLC. Mr. Wells previously worked in the private wealth management division of Goldman Sachs & Co. from 1985 to 2000. Mr. Wells received a B.A. in Economics from the University of Mississippi and an M.B.A. from the Amos Tuck Business School at Dartmouth College.

Robert E. Sobol, MD Chief Executive Officer

Dr. Sobol has served as MultiVir’s Chief Executive Officer since the company was founded and is a member of our board of directors. He has over 25 years of biotechnology entrepreneur and management experience. Dr. Sobol has pioneered the development of novel biological cancer therapies and is an internationally renowned physician-scientist in the fields of molecular cancer treatments and biomarkers. He has founded, held senior management positions and served on the Board of Directors of numerous biotechnology companies. He was a co-founder of Idec Pharmaceuticals (now Biogen), which is one of the world’s largest biotechnology companies, and pioneered the use of monoclonal antibodies for cancer therapy. Dr. Sobol led the research teams responsible for the first experimental gene therapies for the treatment of brain tumors and colon carcinoma. He is the past President of the International Society of Cell and Gene Therapy for Cancer, and previously served on the Clinical Program Review Committee of the National Cancer Institute. Dr. Sobol received a B.A. in Philosophy from Boston University and an M.D. from the Chicago Medical School. He received his clinical training at the University of Southern California Medical Center and at the University of California, San Diego and received Board Certifications in both Internal Medicine and Medical Oncology.

Nicholas Puro, JDPresident, Chief Operating Officer and Chief Financial Officer

Mr. Puro has served as our President, Chief Operating Officer and Chief Executive Officer since 2014. Mr. Puro served as the Chief Executive Officer of CRN Wireless, LLC, an international provider of wireless products and services that facilitates the communication and monitoring of data signals, from February 2012 to March 2013. Mr. Puro also served as Managing Director of e3 Investment Partners, a family investment fund, from November 2010 through February 2014. Mr. Puro served as President of Temptime Corporation, a global medical device manufacturing company, from August 2004 to October 2010. Mr. Puro was a partner at Edelson Technology Partners, a venture capital firm, from August 1998 to August 2005. Prior to joining Edelson, Mr. Puro served as a venture capital attorney involved with transactional work for a number of venture capital funds. Mr. Puro received a B.S. in Accounting from Seton Hall University and a J.D. from Fordham Law School.

Kerstin Menander, MD, PhDVice President Clinical Affairs

Dr. Menander has served as our Vice President Clinical Affairs since November 2009. Previously, Dr. Menander served in senior-level management positions at Syntex, Abbott and several smaller biotech companies such as Collagen Corporation, Cell Pathways Inc. and Introgen Therapeutics. She has also served as Chairperson of the Scientific Affairs Committee of the National Pharmaceutical Council trade organization broad and long experience in the US and international pharmaceutical, biotechnological, scientific, regulatory and medical arenas and marketing. Dr. Menander received her M.D., Ph.D (cum laude) at the University of Lund Sweden where she also served as Associate Professor.

Sunil Chada, PhDChief Scientific Officer

Dr. Chada has served as our Vice President and Chief Scientific Officer since July 2011. Previously, Dr. Chada was the Vice President of Translational Medicine at Intrexon Corporation. Dr. Chada also served as adjunct faculty at the M.D. Anderson Cancer Center of the University of Texas. Dr. Chada was also involved in discovery and preclinical research at Chiron Corporation and Viagene Inc. Dr. Chada received a B.S. from the Department of Cell and Molecular Biology at Kings’ College, University of London, an M.S. in Molecular Biology from the University of California at Los Angeles, and a Ph.D. in Molecular Genetics and Microbiology from the University of Massachusetts Medical School.

Max W. Talbott, PhDVice President Regulatory Affairs

Dr. Talbott has served as our Vice President of Regulatory Affairs since November 2009. Previously, Dr. Talbott served as the Senior Vice President of Worldwide Regulatory Affairs at Bristol-Myers Squibb/DuPont. Dr. Talbott also held various positions at Sanofi-Aventis U.S. LLC, Eli-Lilly and Company, the FDA and Warner-Lambert Company LLC. Dr. Talbott received a B.S. in Biology and an M.A. in Physiology from Ball State University, and a Ph.D. in Immunology and Pharmacology from Rutgers University.